BSEM BioStem Technologies, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1658678 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets57.9%
Debt / equity0.00x
Current ratio0.73x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2025Q32025-09-30 | 2025Q22025-06-30 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $7.64M | $7.90M | $10.47M | $10.96M |
| Cost of revenue | $3.35M | $3.06M | $1.20M | $685,177 |
| Gross profit | $4.29M | $4.84M | $9.27M | $10.28M |
| R&D expense | $481,189 | $733,616 | $1.96M | $1.96M |
| SG&A expense | $7.54M | $6.50M | $4.50M | $6.87M |
| Operating income | -$9.78M | -$8.40M | $1.45M | $112,759 |
| Pretax income | -$11.38M | -$8.97M | $1.47M | $177,953 |
| Income tax | $0 | $0 | $707,677 | $167,340 |
| Net income | -$11.38M | -$8.97M | $761,052 | $10,613 |
| EBITDA | -$9.07M | -$7.71M | $1.51M | $173,498 |
| EPS (basic) | -0.64 | -0.52 | 0.05 | 0.00 |
| EPS (diluted) | -0.64 | -0.52 | 0.03 | 0.00 |
| Weighted avg. shares (diluted) | 17.86M | 17.33M | 22.79M | 23.42M |
| Balance sheet | ||||
| Cash & equivalents | $971,145 | $6.96M | $27.16M | $30.84M |
| Receivables | $6.60M | $6.62M | — | — |
| Inventory | $6.45M | $4.71M | — | — |
| Current assets | $16.13M | $20.78M | — | — |
| PP&E, net | $4.38M | $4.42M | — | — |
| Goodwill | $1.53M | $1.53M | — | — |
| Intangibles | $20.86M | $21.36M | — | — |
| Total assets | $43.58M | $48.82M | — | — |
| Current liabilities | $22.17M | $21.20M | — | — |
| Long-term debt | $0 | $0 | — | — |
| Total debt | $0 | $0 | — | — |
| Total liabilities | $25.25M | $21.20M | — | — |
| Shareholders' equity | $18.33M | $27.61M | $49.16M | $47.23M |
| Net debt | -$971,145 | -$6.96M | — | — |
| Shares outstanding | 18.68M | 17.84M | — | — |
| Cash flow statement | ||||
| Operating cash flow | -$8.82M | — | -$2.36M | — |
| Capital expenditure | $0 | — | $2.44M | — |
| Free cash flow | -$8.82M | — | -$4.80M | — |
| Investing cash flow | -$169,090 | — | -$1.19M | — |
| Financing cash flow | $3.00M | — | -$135,000 | — |
| Depreciation & amortization | $706,661 | $689,317 | $57,644 | $60,739 |
| Stock-based compensation | $1.01M | $1.00M | $504,787 | $495,874 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.